Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.02 -0.09 (-0.34%)
Streaming Delayed Price Updated: 1:09 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Bridge City Capital Loads Up Onto Innovation Stock With Over 31,000 Shares ↗
Post-trade holding: 47,342 shares valued at approximately $6.12 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity ↗
PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors. 
Via Chartmill
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Preview: Pacira BioSciences's Earnings ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗
 
Via Benzinga
News headline image
Pacira (PCRX) Q2 Revenue Rises 1.7% ↗
Via The Motley Fool
News headline image
Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss ↗
Pacira BioSciences (PCRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares were flat post-release as investors weighed the performance. The company highlighted... 
Via Chartmill
News headline image
Insights Ahead: Pacira BioSciences's Quarterly Earnings ↗
 
Via Benzinga
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering ↗
PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors. 
Via Chartmill
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals ↗
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability and steady growth, making it a potential candidate for value investors. 
Via Chartmill
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals ↗
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability, steady growth, and reasonable financial health, making it a candidate for value investors. 
Via Chartmill
News headline image
Where Pacira BioSciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—a stock with solid growth prospects and a reasonable valuation. ↗
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching 
Via Chartmill
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. ↗
PACIRA BIOSCIENCES INC may be an undervalued stock option. NASDAQ:PCRX retains a strong financial foundation and an attractive price tag. 
Via Chartmill
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued. ↗
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars ↗
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and... 
Via Stocktwits
Topics Intellectual Property
News headline image
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps ↗
Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039. 
Via Benzinga
Topics Intellectual Property
News headline image
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice ↗
As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Wondering what's happening in today's after-hours session? ↗
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. ↗
PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.